Clinical trials
catalyst calendar across sponsors →Studies where RAPP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional
Held by 7 tracked-famous managers (D. E. Shaw & Co., Inc., MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, AQR CAPITAL MANAGEMENT LLC, +2 more) · FINRA short interest 7.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1NCT07563881Median Percent Change in Seizure FrequencyRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: RAP-219, RAP-219 · Other: Placebo | Focal Seizure, Epilepsy, Focal Epilepsy | 333 | Jul 2029 | ≤ 1,077 d | 2026-08-13 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresNCT07594119Median Percent Change in Seizure FrequencyRandomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: RAP-219, RAP-219 · Other: Placebo | Focal Seizure, Epilepsy, Focal Epilepsy | 312 | Jul 2029 | ≤ 1,077 d | 2026-08-05 |
| A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresNCT07219407Incidence of treatment-emergent adverse events (TEAEs)Open-label · Treatment | Phase 2 | Recruiting | Drug: RAP-219 | Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure | 30 | 2028-02-03 | in 533 d | 2026-01-23 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderNCT07046494Young Mania Rating Scale (YMRS)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: RAP-219 · Other: Placebo | Bipolar 1 Disorder | 253 | 2026-08-05actual | — | 2026-08-10 |
| Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyNCT06377930Change in long episode frequency during the treatment period compared to pre-treatment baseline: Responder proportion, Percent Change Percent changeOpen-label · Treatment | Phase 2 | Completed | Drug: RAP-219 | Focal Onset Seizures | 30 | 2025-09-26actual | — | 2026-02-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19